Come see a special preview of the next-generation PRIMA glasses at the Potsdam Meeting from April 17–18.
The new glasses are updated for functionality, including integrated processing and eye tracking.
Stop by our booth to connect with our team and learn more about the PRIMA system for GA/AMD.
TechCrunch’s Tim Fernholz reports: “Max Hodak’s Science Corp. is preparing to place its first sensor in a human brain.” Science Advisor Dr. Günel says: “The idea of using natural connections through neurons and creating a biological interface between the electronics and the human brain is genius.”
Come visit us at the VM Retina Meeting 2026 in Munich from Thurs, April 16 – Sat, April 18 – booth #7.
Meet our team and see the PRIMA implant, next-gen glasses, and implantation device up close.
Read more here: www.science.xyz/news/if-design-award
The independent jury describes Axon Terminal as “a portable neural signal simulator, like an ‘MP3 player for neural data.’ It enables researchers to load, browse, and play pre-recorded neural signals, offering a precise yet approachable interface for neuroscience experimentation.”
Science has won the iF Design Award 2026 for Product Design in the Medical/Healthcare category for the Axon Terminal, part of the Science Ecosystem. Science partnered with the design firm Card79 on the project.
Our CEO Max Hodak joined Juan Benet for a conversation about BCI breakthroughs at Science and how they will benefit patients.
Science Chief Scientific Officer and Co-Founder Alan Mardinly answers the question “What if we could restore vision, communicate directly with the brain, and even extend human life with living, engineered biology?” Click the link in the comments to watch the full episode.
Geographic atrophy due to AMD is the leading cause of irreversible blindness. @nejm.org's Katerina Lin, MD, explains Science’s PRIMA clinical trial and how the system drove significant visual acuity improvements at 12 months. Link in comments.
Arena Magazine profiles Science CEO @maxhodak.bsky.social and details the breakthrough of the PRIMA retinal implant for AMD, the groundbreaking work on Biohybrid, and the new possibilities brain-computer interfaces offer patients.
Read the profile in the comments.
As we accelerate the development of our Biohybrid BCI program, we are thrilled to welcome Dr. Murat Günel as Science's new Medical Director for Brain-Computer Interfaces. Dr. Günel is Chair of Neurosurgery at Yale School of Medicine and a Member of the National Academy of Medicine.
Though this sample is invisible to the naked eye, imaging it takes 124 GB of storage, equivalent to ~5x the entire English Wikipedia text.
Science CEO, Max Hodak, joined POLITICO for 5 Questions: www.politico.com/newsletters/...
"People use [AI] every day, but it is still underestimated the degree to which it is going to change everybody’s lives over the next decade. We’re really now starting to see that. [AI agents] are no longer just a curiosity. They’re now having economic impacts that are going to accelerate."
@news.upmc.com
“It’s the first time that any attempt at vision restoration has achieved such results in a large number of patients… This is really something we couldn’t have dreamt of when we started on this journey more than two decades ago.”
Read more here: www.science.xyz/news/jose-sahel-questions
In a new interview, José-Alain Sahel, MD, a senior author of the PRIMA clinical trial now published in @nejm.org, shares his opinion on the resilience required to turn a decades-old concept into clinical reality.
"...we have three programs at Science: our work in the retina [for blindness]...our biohybrid neural interface…and critical care life support”, shared Max Hodak, Science’s CEO. “If Medtronic was started in 2021, what are the projects that they would be taking on for the next 20 years?”
Watch the full interview here: www.youtube.com/watch?v=5gsp...
"I think there's going to be a bunch of BCI companies going after different applications where different types of probes will make sense. To me, it firmly feels like we're in the takeoff era."
Science founder and CEO Max Hodak joined YCombinator to talk about the future of brain-computer interfaces
Join the Science Patient Registry at patients.science.xyz
Science's PRIMA clinical trials are expanding to Australia, and will include inherited retinal diseases, such as Stargardt disease and retinitis pigmentosa.
Read more here: www.science.xyz/news/series-c
We’ve closed a $230 million Series C financing. The deal was oversubscribed with demand in excess of our capital needs, and brings the total capital invested into the company to approximately $490 million since our founding in 2021.
